Topics

Regeneron Announces Positive Results from its Phase 3 Trial of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

13:37 EDT 15 Aug 2019 | Speciality Pharma Journal

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive pivotal Phase 3 results for evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody, in patients with homozygous familial hypercholesterolemia (HoFH). Patients with HoFH have severely elevated levels of bad cholesterol (otherwise known as low-density lipoprotein cholesterol, or LDL cholesterol), and often experience early atherosclerotic disease, sometimes suffering cardiac …

Original Article: Regeneron Announces Positive Results from its Phase 3 Trial of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

NEXT ARTICLE

More From BioPortfolio on "Regeneron Announces Positive Results from its Phase 3 Trial of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...